Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study
- Authors
- Bang, Soo-Mee; Kang, Jin-Hyoung; Hong, Min Hee; Ahn, Jin-Seok; Oh, So Yeon; Baek, Jin Ho; Choi, Yoon Ji; Shin, Seong Hoon; Kim, Young-Joo; Gil, Ha-Yeong; Park, Hyung-Eun; Lee, Juneyoung; Park, Eun-Lyeong
- Issue Date
- 18-1월-2021
- Publisher
- SAGE PUBLICATIONS INC
- Keywords
- cancer; venous thromboembolism; low-molecular-weight heparin; direct oral anticoagulants
- Citation
- CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, v.27
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Volume
- 27
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/50088
- DOI
- 10.1177/1076029620979575
- ISSN
- 1076-0296
- Abstract
- This study assessed epidemiologic data and clinical outcomes, including venous thromboembolism (VTE) recurrence and bleeding events, in patients with cancer-associated VTE, and assessed factors associated with clinical outcomes. Data were extracted from retrospective medical-chart review of adult patients diagnosed with cancer-associated deep vein thrombosis or pulmonary embolism who received anticoagulation treatment for >= 3 months. Patients were classified by: low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOACs), and other anticoagulants. First VTE recurrence and bleeding events, and factors associated with their occurrence, were assessed during the initial 6 months of treatment. Overall, 623 patients (age: 63.7 +/- 11.3 years, 49.3% male) were included (119, 132, and 372 patients in LMWH, DOACs and other anticoagulants groups, respectively). The cumulative 6-month incidence of VTE recurrence was 16.6% (total), 8.3% (LMWH), 16.7% (DOACs), and 20.7% (other); respective bleeding events were 22.5%, 11.0%, 12.3%, and 30.7%). VTE recurrence and bleeding rates differed only between LMWH and other anticoagulants (HR 2.4, 95% CI: 1.2-5.0 and 3.6, 1.9-6.8, respectively). These results highlight the importance of initial VTE treatment choice for preventing VTE recurrence and bleeding events. LMWH or DOACs for >= 3 months can be considered for effective VTE management in cancer patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.